Breaking News

AbbVie Launches New Biopharma Company

Resumes Abbott’s research-based business

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie has launched as an independent biopharmaceutical company, as Abbott completed the separation from the research arm of its pharmaceutical business.   AbbVie launches with an estimated $18 billion in annual revenues, a team of experienced senior leaders, and a broad portfolio that includes Humira, AndroGel, Lupron, Synagis, Creon, Synthroid, Kaletra, Norvir and Zemplar. The company will also keep the Abbott Contract Manufacturing business.   “Today AbbVie launches with an outstanding ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters